STK-001 ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
140	ドラベ症候群	2

140. ドラベ症候群

---

臨床試験数 : 104 /  薬物数 : 61 - (DrugBank : 14) / 標的遺伝子数 : 48 - 標的パスウェイ数 : 63

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04740476 (ClinicalTrials.gov)	January 21, 2021	2/2/2021	An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome	An Open-Label Extension Study for Patients With Dravet Syndrome Who Previously Participated in Studies of STK-001	Dravet Syndrome	Drug: STK-001	Stoke Therapeutics, Inc	NULL	Enrolling by invitation	30 Months	N/A	All	48	Phase 2	United States
2	NCT04442295 (ClinicalTrials.gov)	June 3, 2020	8/6/2020	An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome	An Open-Label Study to Investigate the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Antisense Oligonucleotide STK-001 in Children and Adolescents With Dravet Syndrome	Dravet Syndrome	Drug: STK-001 - Single Ascending Doses;Drug: STK-001 - Multiple Ascending Doses	Stoke Therapeutics, Inc	NULL	Recruiting	2 Years	18 Years	All	70	Phase 1/Phase 2	United States